Curis' small molecule inhibitor featured in AML and MDS study
Curis reported a publication in Nature Cell Biology. The study findings demonstrate that a cancer-causing splicing variant of IRAK4, IRAK4-L, is dominant in the majority of cases of acute myeloid leukemia and myelodysplastic syndromes. Additionally, specific mutations of the U2AF1 splicing factor induce IRAK4-L, which has potential therapeutic targetability by CA-4948, the company's small molecule inhibitor of IRAK4. The findings present inhibition of IRAK4 as a potential option for the treatment of patients with myeloid malignancies expressing IRAK4-L and with U2AF1 mutations. Isoform-switching to the oncogenic form of IRAK4 is also present in a subset of breast, lung and colon cancers. The company is currently evaluating CA-4948 in an ongoing Phase 1 trial in patients with non-Hodgkin lymphoma, including those with MYD88 alterations, with interim data expected in mid-2019. In addition, the company is further investigating the potential of CA-4948 in patients with myeloid malignancies expressing IRAK4-L and with U2AF1 mutations.